Veterinary Medicines

VANGUARD PLUS 7, liofilizat i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań dla psów

Authorised
  • Canine adenovirus 2, Live
  • Canine parainfluenza virus, Live
  • Canine parvovirus, Live
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
  • Canine distemper virus, Live
Download as PDF

Product identification

Medicine name:
VANGUARD PLUS 7, liofilizat i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań dla psów
Active substance:
  • Canine adenovirus 2, Live
  • Canine parainfluenza virus, Live
  • Canine parvovirus, Live
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
  • Canine distemper virus, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, Live
    1584.89
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, Live
    1000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, Live
    10000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Canicola, Inactivated
    740.00
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
    915.00
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Canine distemper virus, Live
    1000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Available in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Polska Sp. z o.o.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1461
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 4/02/2022
Download